Descemet Membrane Endothelial Keratoplasty: Safety and Outcomes. A Report by the American Academy of Ophthalmology

Sophie X. Deng, W. Barry Lee, Kristin M. Hammersmith, Anthony N. Kuo, Jennifer Li, Joanne F. Shen, Mitchell P. Weikert, Roni M. Shtein

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: To review the published literature on the safety and outcomes of Descemet membrane endothelial keratoplasty (DMEK) for the surgical treatment of corneal endothelial dysfunction. Methods: Literature searches were last conducted in the PubMed and the Cochrane Library databases most recently in May 2017. The searches, which were limited to English-language abstracts, yielded 1085 articles. The panel reviewed the abstracts, and 47 were determined to be relevant to this assessment. Results: After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to 20/31, with follow-up ranging from 5.7 to 68 months. At 6 months, 37.6% to 85% of eyes achieved BCVA of 20/25 or better and 17% to 67% achieved BCVA of 20/20 or better. Mean endothelial cell (EC) loss was 33% (range, 25%-47%) at 6 months. Overall change in spherical equivalent was +0.43 diopters (D; range, -1.17 to +1.2 D), with minimal induced astigmatism of +0.03 D (range, -0.03 to +1.11 D). The most common complication was partial graft detachment requiring air injection (mean, 28.8%; range, 0.2%-76%). Intraocular pressure elevation was the second most common complication (range, 0%-22%) after DMEK, followed by primary graft failure (mean, 1.7%; range, 0%-12.5%), secondary graft failure (mean, 2.2%; range, 0%-6.3%), and immune rejection (mean, 1.9%; range, 0%-5.9%). Overall graft survival rates after DMEK ranged from 92% to 100% at last follow-up. Best-corrected visual acuity after Descemet's stripping endothelial keratoplasty (DSEK) ranged from 20/34 to 20/66 at 9 months. The most common complications after DSEK were graft detachment (mean, 14%; range, 0%-82%), endothelial rejection (mean, 10%; range, 0%-45%), and primary graft failure (mean, 5%; range, 0%-29%). Mean EC loss after DSEK was 37% at 6 months. Conclusions: The evidence reviewed supports DMEK as a safe and effective treatment for endothelial failure. With respect to visual recovery time, visual outcomes, and rejection rates, DMEK seems to be superior to DSEK and to induce less refractive error with similar surgical risks and EC loss compared with DSEK. The rate of air injection and repeat keratoplasty were similar in DMEK and DSEK after the learning curve for DMEK.

Original languageEnglish (US)
JournalOphthalmology
DOIs
StateAccepted/In press - 2017

Fingerprint

Descemet Membrane
Corneal Transplantation
Descemet Stripping Endothelial Keratoplasty
Safety
Visual Acuity
Transplants
Endothelial Cells
Air
Injections
Learning Curve
Refractive Errors
Astigmatism
Graft Survival
Treatment Failure
Intraocular Pressure
PubMed
Libraries
Language
Databases

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Descemet Membrane Endothelial Keratoplasty : Safety and Outcomes. A Report by the American Academy of Ophthalmology. / Deng, Sophie X.; Lee, W. Barry; Hammersmith, Kristin M.; Kuo, Anthony N.; Li, Jennifer; Shen, Joanne F.; Weikert, Mitchell P.; Shtein, Roni M.

In: Ophthalmology, 2017.

Research output: Contribution to journalArticle

Deng, Sophie X. ; Lee, W. Barry ; Hammersmith, Kristin M. ; Kuo, Anthony N. ; Li, Jennifer ; Shen, Joanne F. ; Weikert, Mitchell P. ; Shtein, Roni M. / Descemet Membrane Endothelial Keratoplasty : Safety and Outcomes. A Report by the American Academy of Ophthalmology. In: Ophthalmology. 2017.
@article{7392d941ce8643eab17734177dc30d92,
title = "Descemet Membrane Endothelial Keratoplasty: Safety and Outcomes. A Report by the American Academy of Ophthalmology",
abstract = "Purpose: To review the published literature on the safety and outcomes of Descemet membrane endothelial keratoplasty (DMEK) for the surgical treatment of corneal endothelial dysfunction. Methods: Literature searches were last conducted in the PubMed and the Cochrane Library databases most recently in May 2017. The searches, which were limited to English-language abstracts, yielded 1085 articles. The panel reviewed the abstracts, and 47 were determined to be relevant to this assessment. Results: After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to 20/31, with follow-up ranging from 5.7 to 68 months. At 6 months, 37.6{\%} to 85{\%} of eyes achieved BCVA of 20/25 or better and 17{\%} to 67{\%} achieved BCVA of 20/20 or better. Mean endothelial cell (EC) loss was 33{\%} (range, 25{\%}-47{\%}) at 6 months. Overall change in spherical equivalent was +0.43 diopters (D; range, -1.17 to +1.2 D), with minimal induced astigmatism of +0.03 D (range, -0.03 to +1.11 D). The most common complication was partial graft detachment requiring air injection (mean, 28.8{\%}; range, 0.2{\%}-76{\%}). Intraocular pressure elevation was the second most common complication (range, 0{\%}-22{\%}) after DMEK, followed by primary graft failure (mean, 1.7{\%}; range, 0{\%}-12.5{\%}), secondary graft failure (mean, 2.2{\%}; range, 0{\%}-6.3{\%}), and immune rejection (mean, 1.9{\%}; range, 0{\%}-5.9{\%}). Overall graft survival rates after DMEK ranged from 92{\%} to 100{\%} at last follow-up. Best-corrected visual acuity after Descemet's stripping endothelial keratoplasty (DSEK) ranged from 20/34 to 20/66 at 9 months. The most common complications after DSEK were graft detachment (mean, 14{\%}; range, 0{\%}-82{\%}), endothelial rejection (mean, 10{\%}; range, 0{\%}-45{\%}), and primary graft failure (mean, 5{\%}; range, 0{\%}-29{\%}). Mean EC loss after DSEK was 37{\%} at 6 months. Conclusions: The evidence reviewed supports DMEK as a safe and effective treatment for endothelial failure. With respect to visual recovery time, visual outcomes, and rejection rates, DMEK seems to be superior to DSEK and to induce less refractive error with similar surgical risks and EC loss compared with DSEK. The rate of air injection and repeat keratoplasty were similar in DMEK and DSEK after the learning curve for DMEK.",
author = "Deng, {Sophie X.} and Lee, {W. Barry} and Hammersmith, {Kristin M.} and Kuo, {Anthony N.} and Jennifer Li and Shen, {Joanne F.} and Weikert, {Mitchell P.} and Shtein, {Roni M.}",
year = "2017",
doi = "10.1016/j.ophtha.2017.08.015",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Descemet Membrane Endothelial Keratoplasty

T2 - Safety and Outcomes. A Report by the American Academy of Ophthalmology

AU - Deng, Sophie X.

AU - Lee, W. Barry

AU - Hammersmith, Kristin M.

AU - Kuo, Anthony N.

AU - Li, Jennifer

AU - Shen, Joanne F.

AU - Weikert, Mitchell P.

AU - Shtein, Roni M.

PY - 2017

Y1 - 2017

N2 - Purpose: To review the published literature on the safety and outcomes of Descemet membrane endothelial keratoplasty (DMEK) for the surgical treatment of corneal endothelial dysfunction. Methods: Literature searches were last conducted in the PubMed and the Cochrane Library databases most recently in May 2017. The searches, which were limited to English-language abstracts, yielded 1085 articles. The panel reviewed the abstracts, and 47 were determined to be relevant to this assessment. Results: After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to 20/31, with follow-up ranging from 5.7 to 68 months. At 6 months, 37.6% to 85% of eyes achieved BCVA of 20/25 or better and 17% to 67% achieved BCVA of 20/20 or better. Mean endothelial cell (EC) loss was 33% (range, 25%-47%) at 6 months. Overall change in spherical equivalent was +0.43 diopters (D; range, -1.17 to +1.2 D), with minimal induced astigmatism of +0.03 D (range, -0.03 to +1.11 D). The most common complication was partial graft detachment requiring air injection (mean, 28.8%; range, 0.2%-76%). Intraocular pressure elevation was the second most common complication (range, 0%-22%) after DMEK, followed by primary graft failure (mean, 1.7%; range, 0%-12.5%), secondary graft failure (mean, 2.2%; range, 0%-6.3%), and immune rejection (mean, 1.9%; range, 0%-5.9%). Overall graft survival rates after DMEK ranged from 92% to 100% at last follow-up. Best-corrected visual acuity after Descemet's stripping endothelial keratoplasty (DSEK) ranged from 20/34 to 20/66 at 9 months. The most common complications after DSEK were graft detachment (mean, 14%; range, 0%-82%), endothelial rejection (mean, 10%; range, 0%-45%), and primary graft failure (mean, 5%; range, 0%-29%). Mean EC loss after DSEK was 37% at 6 months. Conclusions: The evidence reviewed supports DMEK as a safe and effective treatment for endothelial failure. With respect to visual recovery time, visual outcomes, and rejection rates, DMEK seems to be superior to DSEK and to induce less refractive error with similar surgical risks and EC loss compared with DSEK. The rate of air injection and repeat keratoplasty were similar in DMEK and DSEK after the learning curve for DMEK.

AB - Purpose: To review the published literature on the safety and outcomes of Descemet membrane endothelial keratoplasty (DMEK) for the surgical treatment of corneal endothelial dysfunction. Methods: Literature searches were last conducted in the PubMed and the Cochrane Library databases most recently in May 2017. The searches, which were limited to English-language abstracts, yielded 1085 articles. The panel reviewed the abstracts, and 47 were determined to be relevant to this assessment. Results: After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to 20/31, with follow-up ranging from 5.7 to 68 months. At 6 months, 37.6% to 85% of eyes achieved BCVA of 20/25 or better and 17% to 67% achieved BCVA of 20/20 or better. Mean endothelial cell (EC) loss was 33% (range, 25%-47%) at 6 months. Overall change in spherical equivalent was +0.43 diopters (D; range, -1.17 to +1.2 D), with minimal induced astigmatism of +0.03 D (range, -0.03 to +1.11 D). The most common complication was partial graft detachment requiring air injection (mean, 28.8%; range, 0.2%-76%). Intraocular pressure elevation was the second most common complication (range, 0%-22%) after DMEK, followed by primary graft failure (mean, 1.7%; range, 0%-12.5%), secondary graft failure (mean, 2.2%; range, 0%-6.3%), and immune rejection (mean, 1.9%; range, 0%-5.9%). Overall graft survival rates after DMEK ranged from 92% to 100% at last follow-up. Best-corrected visual acuity after Descemet's stripping endothelial keratoplasty (DSEK) ranged from 20/34 to 20/66 at 9 months. The most common complications after DSEK were graft detachment (mean, 14%; range, 0%-82%), endothelial rejection (mean, 10%; range, 0%-45%), and primary graft failure (mean, 5%; range, 0%-29%). Mean EC loss after DSEK was 37% at 6 months. Conclusions: The evidence reviewed supports DMEK as a safe and effective treatment for endothelial failure. With respect to visual recovery time, visual outcomes, and rejection rates, DMEK seems to be superior to DSEK and to induce less refractive error with similar surgical risks and EC loss compared with DSEK. The rate of air injection and repeat keratoplasty were similar in DMEK and DSEK after the learning curve for DMEK.

UR - http://www.scopus.com/inward/record.url?scp=85029481883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029481883&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2017.08.015

DO - 10.1016/j.ophtha.2017.08.015

M3 - Article

C2 - 28923499

AN - SCOPUS:85029481883

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -